{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Xu J"],"funding":["Overseas Expertise Introduction Project for Discipline Innovation","National Natural Science Foundation of China","Shanghai Collaborative Innovation Program on Regenerative Medicine and Stem Cell Research","Shanghai Pujiang Program","Double First-Class Project"],"pagination":["23"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11040812"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(1)"],"pubmed_abstract":["<h4>Background</h4>The autologous anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy LCAR-B38M has been approved for the treatment of relapsed and refractory multiple myeloma in many countries across the world under the name ciltacabtagene autoleucel. LEGEND-2 was the first-in-human trial of LCAR-B38M and yielded deep and durable therapeutic responses. Here, we reported the outcomes in LEGEND-2 after a minimal 5-year follow-up.<h4>Methods</h4>Participants received an average dose of 0.5 × 10<sup>6</sup> cells/kg LCAR-B38M in split or single unfractionated infusions after cyclophosphamide-based lymphodepletion therapy. Investigator-assessed response, survival, safety and pharmacokinetics were evaluated.<h4>Results</h4>Seventy-four participants enrolled and "],"journal":["Journal of hematology & oncology"],"pubmed_title":["Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial."],"pmcid":["PMC11040812"],"funding_grant_id":["82230006","B17029","82070227","2019CXJQ01","22PJ1409800","WF510162602","82370201"],"pubmed_authors":["Yang SS","Yu SH","Chen SJ","Hou J","Wang BY","Chen Z","Mi JQ","Zhao WH","Liu R","Chen LJ","He AL","Xu J"],"additional_accession":[]},"is_claimable":false,"name":"Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.","description":"<h4>Background</h4>The autologous anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy LCAR-B38M has been approved for the treatment of relapsed and refractory multiple myeloma in many countries across the world under the name ciltacabtagene autoleucel. LEGEND-2 was the first-in-human trial of LCAR-B38M and yielded deep and durable therapeutic responses. Here, we reported the outcomes in LEGEND-2 after a minimal 5-year follow-up.<h4>Methods</h4>Participants received an average dose of 0.5 × 10<sup>6</sup> cells/kg LCAR-B38M in split or single unfractionated infusions after cyclophosphamide-based lymphodepletion therapy. Investigator-assessed response, survival, safety and pharmacokinetics were evaluated.<h4>Results</h4>Seventy-four participants enrolled and ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-06-01T09:17:11.343Z","creation":"2026-04-08T11:05:14.169Z"},"accession":"S-EPMC11040812","cross_references":{"pubmed":["38659046"],"doi":["10.1186/s13045-024-01530-z"]}}